Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Divalproex Sodium Extended-release tablets. The product is ready for launch.
The drug is the generic equivalent of AbbVie Inc’s Depakote ER Extended-release tablets and indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features The product has a market size of approximately $690 million for the 12 months ended March 31, 2014, according to IMS.
According to a release, this ANDA has been approved out of Unit VII (SEZ) formulation facility in Hyderabad.
Aurobindo now has a total of 194 ANDA approvals (168 final approvals including 7 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.